Global Aging Trends Will Spark Demand For MASH Treatments
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
10 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
€10.00
62.0% undervalued intrinsic discount16 Aug
€3.80
1Y
65.9%7D
26.7%